0001261002false--12-312021-12-31FY202200012610022021-01-012021-12-3100012610022021-12-310001261002dei:BusinessContactMember2021-01-012021-12-31iso4217:USDxbrli:sharesiso4217:USDxbrli:shares
|
OMB APPROVAL
|
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
|
OMB Number: 3235-0288
Expires: October 31, 2022
Estimated average burden hours per response..2629.68
|
FORM 20-F
(Mark One)
☐
|
REGISTRATION STATEMENT
PURSUANT TO
SECTION 12(b) OR
(g) OF THE
SECURITIES EXCHANGE ACT OF
1934
|
OR
☒
|
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
|
|
|
|
For the fiscal years ended December 31, 2021, 2020 and
2019
|
OR
☐
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
|
OR
☐
|
SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
|
|
|
|
Date of event requiring this shell company report
_________________
|
|
For the transition period from
to
|
Commission file number
Genoil
Inc.
|
(Exact name of Registrant as specified in its charter)
|
Genoil
Inc.
(Translation of Registrant’s name into English)
Canada
(Jurisdiction of incorporation or organization)
One Rockefeller Center
11th Floor
New York, NY
10020
(Address of principal executive offices)
David Lifschultz, Tel 212-688-8868, e-mail
–
david@lifschultzorganization.com
(Name, Telephone, E-mail and/or Facsimile number and Address of
Company Contact Person)
Securities registered or to be registered pursuant to Section 12(b)
of the Act. None
Title of each class
|
|
Trading
Symbol(s)
|
|
Name of each exchange
on which registered
|
|
|
|
|
|
Securities registered or to be registered pursuant to Section 12(g)
of the Act.
Common Stock, Fully Paid and Non-Assessable Common Shares
Without Par Value quoted on the OTC Markets Quotation
System.
|
(Title of Class)
|
SEC 1852 (05-21)
|
Persons who respond to the collection of information
contained in this form are not required to respond unless the form
displays a currently valid OMB control number.
|
|
(Title of Class)
|
Securities for which there is a reporting obligation pursuant to
Section 15(d) of the Act.
None.
Indicate the number of outstanding shares of each of the issuer’s
classes of capital or common stock as of the close of the period
covered by the annual report.
Common Shares: 640,633,029 as of December 31, 2021,
596,178,029 as of December 31, 2020 and 547,303,029 as of December
31, 2019.
Preferred shares: (zero) as of December 31,
2021.
Indicate by check mark if the registrant is a well-known seasoned
issuer, as defined in Rule 405 of the Securities Act. ☐
Yes ☒ No
If
this report is an annual or transition report, indicate by check
mark if the registrant is not required to file reports pursuant to
Section 13 or 15(d) of the Securities Exchange Act of 1934.
☐ Yes ☒ No
Note – Checking the box above will not relieve any registrant
required to file reports pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934 from their obligations under those
Sections.
Indicate by check mark whether the registrant (1) has filed all
reports required to be filed by Section 13 or 15(d) of the
Securities Exchange Act of 1934 during the preceding 12 months (or
for such shorter period that the registrant was required to file
such reports), and (2) has been subject to such filing requirements
for the past 90 days. ☒ Yes ☐
No
Indicate by check mark whether the registrant has submitted
electronically every Interactive Data File required to be submitted
pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter)
during the preceding 12 months (or for such shorter period that the
registrant was required to submit such files). ☒
Yes ☐ No
Indicate by check mark whether the registrant is a large
accelerated filer, an accelerated filer, a non-accelerated filer,
or an emerging growth company. See definition of “large accelerated
filer,”accelerated filer,” and “emerging growth company” in Rule
12b-2 of the Exchange Act.
Large accelerated filer
|
☐
|
Non-accelerated filer
|
☒
|
Accelerated filer
|
☐
|
Emerging growth company
|
☐
|
If an emerging growth company that prepares its financial
statements in accordance with U.S. GAAP, indicate by check mark if
the registrant has elected not to use the extended transition
period for complying with any new or revised financial accounting
standards† provided pursuant to Section 13(a) of the Exchange Act.
☐
† The term “new or revised financial accounting standard” refers to
any update issued by the Financial Accounting Standards Board to
its Accounting Standards Codification after April 5, 2012.
Indicate by check mark whether the registrant has filed a report on
and attestation to its management’s assessment of the effectiveness
of its internal control over financial reporting under Section
404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the
registered public accounting firm that prepared or issued its audit
report.
Indicate by check mark which basis of accounting the registrant has
used to prepare the financial statements included in this
filing:
U.S. GAAPX
|
☒
|
International Financial Reporting Standards as issued
|
☐
|
Other
|
☐
|
|
|
by
the International Accounting Standards Board
|
|
|
|
If
“Other” has been checked in response to the previous question,
indicate by check mark which financial statement item the
registrant has elected to follow. ☐ Item 17
☐ Item 18
If
this is an annual report, indicate by check mark whether the
registrant is a shell company (as defined in Rule 12b-2 of the
Exchange Act). ☐ Yes ☒ No
(APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY PROCEEDINGS
DURING THE PAST FIVE YEARS)
Indicate by check mark whether the registrant has filed all
documents and reports required to be filed by Sections 12, 13 or
15(d) of the Securities Exchange Act of 1934 subsequent to the
distribution of securities under a plan confirmed by a court. ☐
Yes ☐ No
Contents
PART I
Item 1. Identity of Directors,
Senior Management and Advisers
A. Directors and senior management.
Not required as this is an annual report under the Exchange
Act.
B. Advisers.
Not required as this is an annual report under the Exchange
Act.
C. Auditors.
Not required as this is an annual report under the Exchange
Act.
Item 2. Offer Statistics and
Expected Timetable
Not required as this is an annual report under the Exchange
Act.
Item 3. Key
Information
A. [Reserved]
B. Capitalization and indebtedness.
Not required as this is an annual report under the Exchange
Act.
C. Reasons for the offer and use of proceeds.
Not required as this is an annual report under the Exchange
Act.
D. Risk factors.
Going Concern
To date Genoil has not attained commercially viable operations from
its various patents and technology rights.
The ability of the Company to continue as a going concern is
dependent on commercializing its technologies, achieving profitable
operations and obtaining the necessary financing in order to
develop these technologies further. The outcome of these matters
cannot be predicted at this time. The Company will continue to
review the prospects of raising additional debt and equity
financing to support its operations until such time that its
operations become self-sustaining, to fund its research and
development activities and to ensure the realization of its assets
and discharge of its liabilities. While the Company is expending
its best efforts to achieve the above plans, there is no assurance
that any such activity will generate sufficient funds for future
operations.
General Risk Factors
An investment in the Corporation’s common shares (“Common Shares”)
should be considered highly speculative. In addition to other
information in this Form 20-F, you should carefully consider the
following factors when evaluating Genoil and its business.
Much of the information included in this annual report includes or
is based upon estimates, projections or other “forward-looking
statements”. Such forward-looking statements include any
projections or estimates made by the Corporation and its management
in connection with its business operations. While these
forward-looking statements, and any assumptions upon which they are
based, are made in good faith and reflect Genoil’s current judgment
regarding the direction of its business, actual results will almost
always vary, sometimes materially, from any estimates, predictions,
projections, assumptions or other future performance suggested in
this document.
The section that follows addresses several of the risk factors
related to the Corporation’s operations in more detail.
Genoil has a history of substantial losses and negative
cash flows. It expects these losses and negative cash flows to
continue in the future. If it is unable to make a profit, the
Corporation may not be able to continue to operate its
business.
Genoil has not earned profits to date and it may not earn profits
in the future. Profitability, if achieved, may not be sustained.
The commercialization of its technologies requires financial
resources and capital infusions and future revenues may not be
sufficient to generate the funds required to continue its business
development and marketing activities. If the Corporation does not
obtain sufficient capital to fund its operations, it may be
required to forego certain business opportunities or discontinue
operations entirely.
Genoil has incurred significant losses and expects to continue to
incur significantly greater costs than revenue received.
Consequently, the Corporation expects to incur losses in the near
term. If Genoil achieves profitability, it may not be able to
sustain it. The business of initiating, developing and implementing
inventive or innovative processes is inherently risky. Manpower and
capital employed may not result in the development of a commercial
or economic process. Once successfully developed, there is no
certainty that the intended market will be receptive to the
Corporation’s technology. In all areas of its business, Genoil may
compete against entities that may have greater technical and
financial resources. The Corporation is completely dependent upon
external sources of financing which may not be available on
acceptable or economic terms.
The intellectual property and technology developed by
Genoil may not work in the manner anticipated or the market may not
be receptive to its technology or other new technologies might be
more feasible to implement.
Genoil develops technology for use in various industries. Part of
the risk in this type of undertaking is that the technology may not
perform as expected or its use may not be economical. The
development of intellectual property is expensive and time
consuming and if the developed product is not marketable, then no
revenues will be realized from its development.
The marketability of Genoil’s technologies depends on the ability
of those technologies to meet and adapt to the needs of industry
customers. The markets for Genoil’s technologies may not develop
further and the current level of market acceptance of its products
may decrease or may not be sustainable. In order to continue
marketing its technology, the Corporation must adapt to rapid
changes in technology and customer requirements. The Corporation’s
success will depend, in part, on its ability to enhance its
existing technology, gain market acceptance, and continue to
develop its products to meet increasingly demanding customer
requirements.
Genoil’s technology is still experimental so the demand for
it is unknown. The Corporation’s potential market may not develop
as it anticipates and, accordingly, it may not be able to expand
its business or operate it profitably.
The Corporation’s technology has not been proven in any commercial
venture and, as such, any market for its technology will depend
significantly on its own efforts. As a result, future demand for
its technology is unknown. Genoil believes that many of its
potential customers are not fully aware of the benefits of its
technology. The Corporation must educate potential customers
regarding these benefits and convince them of its ability to
provide complete and reliable services. The market for its
technology may never become viable or grow further. If the market
for its technology does not grow or grows more slowly than it
currently anticipates, its business, financial condition and
operating results would be materially adversely affected.
Key contractors may terminate their
engagements.
Skilled and educated professionals are a fundamental component of
the development of intellectual property. If these key contractors
terminate their engagements with Genoil, the development of its
intellectual property may be hindered or delayed, increasing the
expenses associated with technology development. The Corporation’s
success is dependent on the services of members of its senior
management team. The experience and talents of this team will be a
significant factor in its continued success and growth. The loss of
any senior management member could have a material adverse effect
on its operations and business prospects. Given its financial
situation, Genoil may not be able to retain or replace its key
personnel. The Corporation has no key man insurance.
Genoil has issued common share purchase warrants, options,
price appreciation certificates(PACs) and convertible debt, the
conversion and/or exercise of which would have a dilutive effect on
its earnings per share.
As of December 31, 2021, the following potentially dilutive
instruments were outstanding:
Warrants
|
|
|
150,543,138 |
|
Options
|
|
|
57,890,000 |
|
PACs
|
|
|
550,400,000 |
|
Notes
|
|
|
471,176,400 |
|
|
|
|
1,230,009,538 |
|
Shares o/s
|
|
|
640,633,029 |
|
Pot'l Dil'n
|
|
|
192 |
% |
Furthermore, the Corporation may enter into commitments in the
future which would require the issuance of additional Common
Shares, and it may grant additional stock options. The Corporation
is authorized to issue an unlimited number of Common Shares. Genoil
issues Common Shares for the purpose of raising funds for general
working capital requirements, to acquire additional technology, to
accommodate strategic partnerships, or for the satisfaction of
debts.
Third parties may claim that Genoil infringes their
proprietary rights.
Genoil potentially may be subjected to claims that it has infringed
the intellectual property rights of others. As the number of
products in the oil and gas technology industry increases, the
Corporation may become increasingly subject to infringement claims,
including patent and copyright infringement claims. In addition,
previous employers of its former, current or future employees may
assert claims that such employees have improperly disclosed to
Genoil the confidential or proprietary information belonging to
those employers. Any such claim, with or without merit, could be
time consuming to defend, result in costly litigation, divert
management’s attention from its core business, require it to stop
selling or delay shipping, or cause the redesign of its product. In
addition, Genoil may be required to pay monetary amounts as
damages, for royalty or licensing arrangements, or to satisfy
indemnification obligations that it has with some of its
customers.
Genoil may not be able to protect its proprietary
information.
Genoil relies on a combination of copyright, patents and trade
secret laws, confidentiality procedures, contractual provisions and
other measures to protect its proprietary information. All of these
measures afford only limited protection. These measures may be
invalidated, circumvented or challenged, and others may develop
technologies or processes that are similar or superior to the
Corporation’s technology. Despite its efforts to protect its
proprietary rights, unauthorized parties may attempt to copy
Genoil’s products or to obtain or use information that it regards
as proprietary. Given its size and financial situation, Genoil may
not be ultimately effective in preventing misappropriation of its
proprietary rights.
Genoil’s intellectual property may become outdated or
surpassed by industry improvements.
Genoil is a technology-based company and is involved in developing,
improving, and marketing its technology to customers. There is a
risk that new developments in Genoil’s field of specialty will
arise, making its technology products less marketable. To enhance
its position in the technology industry, the Corporation must
continue to develop and improve its current products and develop
product extensions. There may not be a demand for the products or
capital available to finance their development in the future.
Genoil operates in a competitive market.
The business of providing technology-based solutions to industry is
highly competitive. Some of Genoil’s competitors may have greater
financial and marketing resources, greater market share and name
recognition than it has, which would allow them to quickly develop
market presence in the markets Genoil serves or allow them to
expand into new markets that Genoil intends to serve. Given its
size and financial position, the Corporation may not be able to
effectively compete with these competitors.
Potential expansion and opportunities may
arise.
Genoil may continue to expand its operations or product lines
through the acquisition of additional businesses, products or
technologies. It may not be able to identify, acquire or profitably
manage additional businesses or successfully integrate any acquired
businesses, products or technologies without substantial expenses,
delays or other operational or financial challenges. Furthermore,
acquisitions may involve a number of additional risks, including
the diversion of management’s attention, failure to retain key
personnel, unanticipated events or circumstances and legal
liabilities, some or all of which could have a material adverse
effect on Genoil’s business, results of operations and financial
condition. In addition, acquired businesses, products or
technologies, if any, may not achieve anticipated revenues and
profitability. Acquisitions could also result in potentially
dilutive issuances of equity securities. The Corporation’s failure
to manage its acquisition strategy could have a material adverse
effect on its business, results of operations and financial
condition.
U.S. investors may have difficulty enforcing judgments
against Genoil or its management.
Genoil is incorporated in Canada. Substantially all of its assets
are located outside the United States. As a result, U.S. investors
may not be able to:
|
·
|
effect service of process upon the
Corporation or these persons within the United States; or |
|
|
|
|
·
|
enforce against the Corporation or
these persons in United States courts, judgments obtained in United
States courts, including judgments predicated on the civil
liability provisions of the federal securities laws of the United
States; or |
|
|
|
|
·
|
initiate a derivative suit on the
Corporation’s behalf. |
Climate Disclosures
It is presently undetermined how climate change may affect Genoil’s
business affairs.
Item 4. Genoil’s
Information
A. Genoil’s history and development.
The Company
Genoil was created from an amalgamation on September 5, 1996 under
the Canada Business Corporations Act of Genoil Inc. and
Continental Fashion Group Inc., a public company whose shares
traded on the Alberta Stock Exchange. At the time of the merger,
Continental Fashion Group Inc. had no assets, no liabilities and
did not carry on any business.
The address of its head office is
One Rockefeller Center
11th Floor
New York, NY 10020
and its phone number is 212-688-8868.
Recent History
2021
On June 30, 2021, the Company signed an agreement with the Ras
Madrakah Petroleum Industry Company and Beijing Petrochemical
Engineering Company, a subsidiary of Yanchang Petroleum
International Limited to develop a greenfield Genoil Upgrading
refinery with a capacity of 200,000 barrels per day in the Port of
Duqm in the Sultanate of Oman. Estimated to cost approximately $2.4
billion USD, the project will utilize the Genoil Upgrading
Technology “GHU” Process. Genoil will license its proprietary
technology, process design package, training, and advisory
services, as well as proprietary catalyst and equipment supply.
On August 31, 2021, the Company made a proposal to the Russian
Government to build new pipelines to Asia, which would enable all
Russian natural gas and oil currently produced and supplied to the
EU to be diverted to markets in China. This proposal shields Russia
from German and EU threats relating to the Ukraine and sanctions
relating to the EU Carbon tax.
On October 27, 2021, the Company signed an agreement with the
nephew of King Salman to develop a greenfield Genoil Upgrader with
a capacity of 600,000 barrels per day in the Kingdom of Saudi
Arabia. This complex will be one of the largest refining or
upgrading complexes in the world. Genoil estimates the project to
cost approximately $5 billion USD, the project will exclusively be
utilizing Genoil’s Upgrading Technology “GHU” Process. Genoil will
license its proprietary technology, process design package,
training, and advisory services, as well as proprietary catalyst
and equipment supply.
During the first quarter of 2021, the Company sold a total of
7,450,000 shares of common stock (and warrants) in private
placements for total proceeds of $73,500.
During the first quarter of 2021, the Company issued a total of
1,300,000 shares of common stock as compensation for services. The
fair value of the shares issued (at dates of issuance) totaled
$26,000.
During the second quarter of 2021, the Company sold a total of
14,635,000 shares of common stock (and warrants) in private
placements for total proceeds of $146,350.
During the third quarter of 2021, the Company sold a total of
11,550,000 shares of common stock (and warrants) in private
placements for total proceeds of $115,500.
During the third quarter of 2021, the Company issued a total of
2,300,000 shares of common stock as compensation for services. The
fair value of the shares issued (at dates of issuance) totaled
$23,000.
During the fourth quarter of 2021, the Company sold a total of
6,380,000 shares of common stock (and warrants) in private
placements for total proceeds of $63,900.
During the fourth quarter of 2021, the Company issued a total of
840,000 shares of common stock as compensation for services. The
fair value of the shares issued (at dates of issuance) totaled
$8,400.
During the second quarter of 2021, the Company granted a total of
6,560,000 warrants to certain investors as deemed dividends.
During the third quarter of 2021, the Company granted a total of
500,000 warrants to certain investors as deemed dividends.
During the fourth quarter of 2021, the Company granted a total of
1,926,666 warrants to certain investors as deemed dividends.
2020
Genoil grew its engineering team with the addition of Senior Vice
President of Engineering and Projects, Mr. Slavko Scepanovic, who
over his 30 year career has gained valuable experience, project
management and finance, raising over a billion dollars for energy
projects. He was the deputy director of Optima Group, since 2008.
Slavko, an expert in financing projects, worked with Zarubezhneft
to create the Optima division raising in excess of a billion
dollars for them. He has worked on many oil and gas projects in the
Russian Federation as well. He conducted technical feasibility
studies to determine conditions of financing and to provide funding
for those projects.
John I. Novak has returned as a special advisor to Genoil. John has
more than 25 years of technical and senior management experience
within satellite communications at GM Hughes Electronics. Mr. Novak
served as Chief Business Strategist of Hughes, where he was
responsible for identifying and developing new business campaigns.
He is regularly advising Genoil’s top management and is an integral
part of new business development in Europe. He is responsible for
introducing Genoil to Munich Capital Partners who in turn
introduced Genoil to two refineries in Germany. The parties are in
discussions with Genoil to develop a refining project utilizing the
Genoil GHU technology.
Leslie Vanderpool has also joined Genoil’s advisory board. Leslie
has extensive contacts in the financial world. She will assist
Genoil in introducing Genoil to large funds, assist in business
development and public relations. Leslie also knows many bankers,
industrialists and oil drillers. She will use many of her contacts
to generate interest in Genoil.
JR Owens joined Genoil as Vice President and Chief Operating
Officer of Genoil USA focusing on North America. JR is President of
Cat Bottoms Fuel FS INC. ‘J.R.’ has more than thirty-four years of
oil industry experience as a consultant, global sourcing advisor,
loss control specialist, terminal manager and trader.
Viscount (Lord) Torrington joined Genoil as an advisory board
member. He graduated as a geologist from Oxford University in 1964
and after ten years in the mining industry, largely in Southern
Africa with Anglo American Corporation and Lonrho, he became CEO of
the Attock Oil Company (later Anvil Petroleum), subsequently
serving as Chairman of Expro North Sea, a major UK-based
international service company.
Lord Torrington also served on the House of Lords European
Communities Energy Committee, chairing it from 1984 to 1987. He is
currently a non-executive Director of Lansdowne Oil & Gas PLC
and involved in wildlife charities in Africa. Mr. Torrington’s
career has involved technical, administrative and financial roles
in the worldwide natural resources industries and contact or
negotiation with financial institutions and governments on all
continents.
On July 7, 2020, the Company agreed to satisfy a total of
$3,875,000 then owed to David Lifschultz and Bruce Abbott through
(1) Company reduction of a total of $1,676,984 of the Company’s
receivable balances from David Lifschultz and Bruce Abbott and (2)
Company issuance of new convertible debentures totaling $2,198,016
to David Lifschultz ($1,099,008) and Bruce Abbott ($1,099,008).
Beginning on October 1, 2020, the Company agreed to reimburse David
Lifschultz and Bruce Abbott for out-of-pocket expenses that they
incurred on behalf of the company for occupancy and related costs.
The amount is €10,780, or approximately $12,800 per month and is
split evenly between David Lifschultz and Bruce Abbott. For the
year ended December 31, 2020, the total amount was $38,459.
During the first quarter of 2020, the Company sold a total of
20,950,000 shares of common stock (and warrants) in private
placements for total proceeds of $209,480.
During the first quarter of 2020, the Company issued a total of
3,375,000 shares of common stock as compensation for services. The
fair value of the shares issued (at dates of issuance) totaled
$69,750.
During the second quarter of 2020, the Company sold a total of
8,550,000 shares of common stock (and warrants) in private
placements for total proceeds of $85,490.
During the second quarter of 2020, the Company issued a total of
150,000 shares of common stock as compensation for services. The
fair value of the shares issued (at dates of issuance) totaled
$1,500.
During the third quarter of 2020, the Company sold a total of
7,950,000 shares of common stock (and warrants) in private
placements for total proceeds of $75,500.
During the third quarter of 2020, the Company issued a total of
2,800,000 shares of common stock as compensation for services. The
fair value of the shares issued (at dates of issuance) totaled
$120,000
During the fourth quarter of 2020, the Company sold a total of
5,100,000 shares of common stock (and warrants) in private
placements for total proceeds of $50,990.
2019
On June 12, 2019, the Company announced that Lic. José E. García
Torres, Legal Representative of the company Genoil Inc. and Dr.
Fernando Castrejón Vacio, Director of Product Technology of the
Instituto Mexicano del Petroleo “IMP”, met to sign a Memorandum of
Understanding, which seeks to establish guidelines for cooperation
between Genoil and the IMP to jointly team up to develop business
opportunities in matters of improvement of heavy and extra-heavy
oils in Mexico. The interest of this Memorandum includes the joint
search for business opportunity, as well as the development of
potential investments in service projects, the scaling of products,
provision of technological services, consulting and specialized
advice, promotion of investment, specialized training and marketing
in everything related to the Processing of Heavy Crude Oil, as well
as for the process of Hydrotreating. Also present for the signing
ceremony was Dr. Jorge Ancheyta Juárez, Product Manager for the
Transformation of Crude of IMP and Genoil engineer Mario Alberto
Carreón Rascón.
On July 3, 2019, the Company signed an advisory fee agreement with
Tuimaada-Neft, which is a leading oil and gas company in Russia
with an estimated 850 million tons of oil equivalent. This
agreement builds from our previous LOI that was signed in the
fourth quarter 2017. Genoil will advise and possibly have a
significant role in these development projects, which will include
EPC (engineering, procurement and construction), equity and debt
financing, oil field services, as well as oil field operations and
natural gas development.
On October 7, 2019, the Company announced that the largest bank in
China and the largest bank in the world by total assets, deposits,
loans, number of customers and number of employees has been
formally retained. They have been working for the past several
months to bring strategic investors and finance for development the
massive Velikoye oil field in Russia.
On October 10, 2019, the Company announced that Andrey Sergeev is
joining Genoil Inc. (the “Company”), through its United States
subsidiary, as Chief Geologist. Mr. Sergeev is a highly experienced
geologist whose worldwide career has led him to be well-regarded by
his peers throughout the industry.
B. Business overview.
General Development of the Business
Genoil’s principal business is the development of technologies
relating to the oil and gas industry. Its present goal is to
commercialize its technologies internationally.
The Corporation owns rights to several patented and proprietary
technologies. A number of products that have been created from
these technologies are under development. None of its technologies
have been commercialized. A discussion of these products
follows.
No consideration has been given to consumer boycotts as a result of
operations in Countries of Particular Concern as defined by the
International Religious Freedom Act of 1998. Genoil is a
Canadian company and as such the International Religious
Freedom Act of 1998 does not apply to its operations. The
Corporation does not produce consumer products.
Genoil formed a corporation in the Middle East with SBK Commercial
Business Group in the United Arab Emirates. The corporation is
named “Genoil Emirates”.
The purpose of this new corporation is to create projects in the
U.A.E. for all of Genoil’s technologies, including:
desulfurization, oil upgrading and recycling, water purification
port technologies, well testing, and sand cleaning. Currently the
United Arab Emirates has the seventh largest oil reserves in the
world and is looking to expand production.
The Genoil Emirates joint venture between Genoil and SBK Commercial
Business Group has significant promise. Genoil Emirates has
established its head office in Riyadh, 11321 Kingdome of Saudi
Arabia. The address is Building B, Near Gulf Commercial Complex
Olaya, P.O. Box: 230032. It also has a branch location at Khober
DAMAM, Block 7 Office 32 Khober, Telephone: +96614633181 Facsimile:
+96614664763.
Pilot Heavy Oil Upgrader
Genoil has been primarily involved in the development and
commercial applications of its proprietary heavy oil upgrading
technology – the Genoil Hydroconversion Upgrader (GHU®).
The GHU® converts sour (high sulphur), heavy hydrocarbon feed
stocks into lighter oil with higher quality distillates for
conventional refining. The GHU® process uses a hydrogen enrichment
methodology based on catalytic hydrogenation and flash
separation.
The GHU®’s unique intellectual property is in its hydroconversion
design and mixing devices. A GHU® provides greater mass/heat
transfer between hydrogen, crude and catalyst. As a result,
hydroconversion can be achieved at mild operating conditions.
Sour, acidic, heavy crude and residual by-products are converted
into lighter distillates, increasing the API (or lowering the
density), while maximizing denitrogenation, desulphurisation and
demetalisation to meet new regulatory requirements. The upgraded
crude product will have higher yields of naphtha, distillates and
vacuum gas oil with reduced levels of contaminants such as sulphur,
nitrogen and metals. Genoil’s process is designed specifically to
eliminate most of the sulphur from the feed stocks.
The Genoil GHU Upgrader has been designed to remove 99.5% of the
sulphur, as shown in its latest tests, while lightening the oil at
the same time, significantly raising its API gravity.
The Genoil Upgrading Process yields zero waste and consumes no
external energy or hydrogen, deriving its hydrogen and energy from
its own residue. The cost structure is therefore much lower than
standard upgrading processes in hydrogenation and does not give off
a waste byproduct such as coking of 30%.
Oil/Water Separation
The Genoil Water Treatment Department has increased its
significance in the business model of the Corporation. Initially
developed for the bilge area of a ship, the Crystal Separator is
suitable for a wide range of applications, including off-shore oil
platforms, wastewater treatment plants, refineries, gasoline
service stations and ports. Genoil’s Crystal Sea oil and water
separator is a compact unit that is able to handle small volumes
from 2 GPM to 20 GPM using a compartmental process.
The acquisition of 100% of the issued and outstanding common shares
of Two Hills Environmental Inc. conveys to Genoil surface title to
147 acres of land, together with certain subsurface mineral rights
contained within 2,500 adjacent acres. These multiple salt caverns
could potentially be utilized for a variety of purposes including
waste oil disposal, gas storage reservoirs and waste water
disposal.
This site has potential as a waste oil/water disposal and treatment
facility due its convenient proximity to several waste disposal
companies. Alternatively, several of these massive salt caverns
could become natural gas storage facilities. Any development is
subject to obtaining the proper permits from the necessary
regulatory agencies, further detailed economic analysis and
obtaining appropriate financing.
Two Hills was initially formed to enter into the oilfield waste
disposal industry by capitalizing upon its current undeveloped
asset base. This asset base is comprised of a site under which very
large salt caverns have been formed in the Lotsberg Formation
beneath the earth’s surface. Such caverns are prized in the
oilfield disposal industry due to their efficacy and safety as a
destination for oilfield wastes.
Revenues from Product Sales
The majority of Genoil’s products continue to be at the
commercialization stage and have not recently produced
revenues.
Expenditures Relating to the Sale of Products
Genoil is primarily involved in the development of its technologies
for commercial application. The Company has been building its
internal capabilities. Genoil utilizes independent contractors to
provide engineering and other services for projects as needed. The
operational sites are at – Two Hills AB, and New York, NY.
Genoil does not intend to commit to any expenditures of any other
nature, beyond expenditures necessary for the development and
maintenance of its technologies, in the near future.
Geographic Markets
The Company markets its technology mainly to potential customers in
the Middle East, Russia and China. The markets for Genoil’s
products are global.
Intellectual Property Rights
Genoil has been granted 7 US patents (Patent nos. 6,527,960;
7,001,502; 7,014,756; 5,603,825, 7,510,689, 7,704,400, and,
7,754,076), 2 Canadian patents (No. 2,243,142 and 2,306,069).
Genoil either owns or licenses the rights to all intellectual
properties used in its products.
Genoil has copyright, patent rights and trademarks, which are
necessary and contribute significantly to the preservation of its
competitive position in the markets which it addresses. It is
possible that the Corporation’s patents and other intellectual
property will be challenged, invalidated or circumvented by third
parties in the future. In the future, it may not be able to obtain
necessary licenses on commercially reasonable terms. Genoil enters
into nondisclosure agreements with its suppliers, contractors and
employees, as appropriate, so as to limit access to and disclosure
of its proprietary information. These measures may not suffice to
deter misappropriation or independent third party development of
similar technologies, which may adversely affect the
Corporation.
Sales, Marketing and Distribution
Genoil intends to market its products and license its GHU
technology throughout the world’s oil refining and production
industry
Competition
Genoil is aware that several other companies may be presently
pursuing the development of technologies in the oil and gas
industry. It acknowledges that it is possible that some of these
technologies may be similar in nature to its products and
technologies. Such companies, should they be involved in selling or
developing the same technology as Genoil, may be potential
competitors to the Corporation. The Company believes that its
patented fixed bed catalyst hydroprocessing technology in the GHU
is competitively advantaged in the market by virtue of the expected
comparatively low capital and operating costs and high product
yields for operators relative to other coking or hydroprocessing
products.
Government Regulations
There are several government regulations with which Genoil must
comply. Failure to comply with these regulations could adversely
affect its business. Certain government regulations require the
imposition of standards that are normally a part of industry
knowledge, and as such, would be understood and acted upon by the
Corporation in the normal course of doing business.
Genoil, as a producer of technology and intellectual property, is
not generally subject to environmental regulations. Genoil
specializes in mechanical processes and as such its regular
operations do not fall within the scope of environmental protection
legislation.
The Corporation was subject to securities regulation in the
Canadian jurisdictions in which it was a reporting issuer. As an
issuer with securities traded on the TSX Venture Exchange, the
Company was subject to its rules. The Corporation’s shares are now
quoted on the Over the Counter (OTC) Markets Quotation System and
as such, the Corporation is subject to the OTC listing
requirements.
Plan of Operation
The Company does not expect to generate significant revenue or cash
flow from its technologies or services for the 2022 year, and
possibly beyond.
The Company expects revenue and cash flow to be generated in staged
phases following the execution of definitive agreements.
Genoil expects to generate revenues for the design, implementation
and procurement of its GHU® systems and/or the licensing of its
intellectual property.
The Corporation has accumulated losses of $95.4 million to year
ended December 31, 2021 and is not realizing any cash flow as it
has not to date attained commercial operations in connection with
its various patents and technology rights.
Since inception, Genoil has principally been a technology
development company. In the recent past, commercialization efforts
have been underway for Genoil’s GHU®. Genoil is marketing its GHU®
(and related engineering and design services) to refiners and
producers of sour, heavy crude around the world. The Company
believes that there is strong market potential for this
technology.
The Company continues to focus its efforts on securing commercial
applications for its heavy oil upgrading and oil-water separation
technologies and exploring new avenues in energy related
industries.
At the present time intensive efforts are being made in the Middle
East, Africa, the Caribbean, Mexico, Canada, Russia and Asia to
market the GHU Upgrader and Crystal Sea Bilge Cleaning Units for
ports. Agents that are not performing are being changed and new
agents are being signed up to accelerate our efforts to roll out
the technologies.
Genoil is aggressively marketing its GHU Upgrader technology to
those countries and companies that have substantial heavy oil
reserves as “peak oil” in light oil already has arrived in our
estimation, and a move developing and upgrading heavy oil is around
the corner.
Genoil has announced that the USPTO has allowed a patent for the
reactor of its sand decontamination process. The sand
decontamination system has also been patented recently and the two
patents form a valuable addition to the intellectual property of
Genoil. The reactor plays a key role in the sand decontamination
process and its features are designed to effectively remove oil
from sand, separate oil from sand and water and recover the oil in
the reactor for reuse. An innovative method is utilized for
extracting oil from sand and removing the oil from the path of the
sand.
C. Organizational structure.
David Lifschultz has headed Genoil as CEO since 2001. Since working
for Genoil, David has not received any cash compensation nor has he
sold any Genoil stock. No executives or board members of Genoil
receive any cash compensation. They receive only shares and options
or Price Appreciation Certificates.
The Company has been building its internal capabilities. Genoil
utilizes independent contractors to provide engineering and other
services for projects as needed. The operational sites are at – Two
Hills AB and New York, NY.
The company seeks to work through commission agents who will
receive compensation only when revenues are generated.
Some consultants and agents generally act as representatives on
Genoil’s behalf with respect to commercial opportunities in their
respective cities and countries. The Corporation intends to rely
upon the services of these representatives and to remunerate them
by means of sales commissions and incentive stock options.
Genoil has the following subsidiaries:
|
·
|
Genoil USA Inc., incorporated in
Delaware, United States, which is a wholly owned subsidiary of
Genoil. |
|
·
|
Genoil Emirates LLC, incorporated in the United Arab Emirates,
which will focus upon the fields of oil and water processing and
treatment in the United Arab Emirates. Emirates LLC is jointly
owned by S.B.K. Commercial Business Group LLC and Genoil. As of
December 31, 2021, Emirates LLC had not yet commenced operations
and holds no assets.
|
|
·
|
Two Hills Environmental Inc. incorporated in Canada and registered
in Alberta, which is a wholly owned subsidiary of Genoil. Two Hills
was formed to enter into the oilfield waste disposal industry by
capitalizing upon its current undeveloped asset base. The asset
base comprises a site under which three salt caverns have been
formed in the Lotsberg Formation beneath the earth’s surface. Such
caverns are used in the oilfield disposal industry as a destination
for oilfield wastes.
|
D. Property, plant and equipment.
Human Resources and Facilities
The Company has been building its internal capabilities. Genoil
utilizes independent contractors to provide engineering and other
services for projects as needed. The operational sites are at –Two
Hills, Alberta and New York, NY. The Company seeks to work through
commission agents who will receive compensation when revenues are
generated. Management has been aggressive in attracting talented
individuals who are very experienced, knowledgeable and will assist
Genoil in realizing its objectives in different markets.
The facilities operated by the Corporation are not subject to
environmental protection legislation and to its knowledge no
environmental issues exist that would potentially affect its
utilization of its assets.
Item 4A. Unresolved Staff
Comments
Not applicable.
Item 5. Operating and Financial
Review and Prospects
Forward-Looking Statements
Statements in this report, or any document filed by Genoil with the
different governing authorities, by or on behalf of it, to the
extent not directly and exclusively based on historical events,
constitute “forward-looking statements”. These statements represent
the Corporation’s intentions, plans, expectations, and beliefs, and
no assurance can be given that the results described in such
statements will be achieved.
Forward-looking statements include, without limitation, statements
evaluating market and general economic conditions in the following
sections, and statements regarding future-oriented revenues, costs
and expenditures. Investors are cautioned not to place undue
reliance on these forward-looking statements, which reflect
management’s analysis only as of the date of this document. These
forward-looking statements are subject to certain risks and
uncertainties that could cause actual results to differ materially.
Such risks and uncertainties with respect to the Corporation
include the effects of general economic conditions, changing
foreign exchange rates and actions by government authorities,
uncertainties associated with legal proceedings and negotiations,
industry supply levels, competitive pricing pressures and
misjudgements in the course of preparing forward-looking
statements.
Genoil disclaims any intention or obligation to update or revise
any forward-looking statements, whether as a result of new
information, future events or otherwise.
A. Operating results
Overview
Genoil’s financial statements are prepared in accordance with
accounting principles generally accepted in the United States of
America (“GAAP”), audited in accordance with the standards of the
Public Company Accounting Oversight Board (United States), and are
presented in US dollars unless otherwise indicated.
Genoil is actively involved in the marketing, development and
commercial applications of its proprietary technologies.
To December 31, 2021, the Corporation has incurred significant
operating losses. The Corporation expects to continue to have
operating losses during the next year and expects to fund its
operations in the near term from capital stock offerings and
project loans.
As Genoil’s business has not yet generated revenue from operations,
the Company requires cash infusions on a regular basis as it seeks
to grow, develop and market its technologies.
The Corporation will continue to review the prospects of raising
additional debt and equity financing to support its operations
until such time that its operations become self-sustaining, fund
any further research and development activities, and ensure the
commercial realization of its assets and discharge of its
liabilities. While the Corporation is expending its best efforts to
achieve the above plans, there is no assurance that any such
activity will generate sufficient funds for operations.
Acquisition
No recent acquisitions.
B. Liquidity and Capital Resources
Genoil’s business is capital intensive, requiring cash infusions on
a regular basis as it seeks to grow its business. The Corporation
expects to be able to fund its capital expenditure program to the
end of 2022 using working capital and, to the extent required or
desirable, through funds raised in the capital markets and short
term loans.
During the first quarter of 2021, the Company sold a total of
7,450,000 shares of common stock (and warrants) in private
placements for total proceeds of $73,500.
During the first quarter of 2021, the Company issued a total of
1,300,000 shares of common stock as compensation for services. The
fair value of the shares issued (at dates of issuance) totaled
$26,000.
During the second quarter of 2021, the Company sold a total of
14,635,000 shares of common stock (and warrants) in private
placements for total proceeds of $146,350.
During the third quarter of 2021, the Company sold a total of
11,550,000 shares of common stock (and warrants) in private
placements for total proceeds of $115,500.
During the third quarter of 2021, the Company issued a total of
2,300,000 shares of common stock as compensation for services. The
fair value of the shares issued (at dates of issuance) totaled
$23,000.
During the fourth quarter of 2021, the Company sold a total of
6,380,000 shares of common stock (and warrants) in private
placements for total proceeds of $63,900.
During the fourth quarter of 2021, the Company issued a total of
840,000 shares of common stock as compensation for services. The
fair value of the shares issued (at dates of issuance) totaled
$8,400.
During the second quarter of 2021, the Company granted a total of
6,560,000 warrants to certain investors as deemed dividends.
During the third quarter of 2021, the Company granted a total of
500,000 warrants to certain investors as deemed dividends.
During the fourth quarter of 2021, the Company granted a total of
1,926,666 warrants to certain investors as deemed dividends.
During the first quarter of 2020, the Company sold a total of
20,950,000 shares of common stock (and warrants) in private
placements for total proceeds of $209,480.
During the first quarter of 2020, the Company issued a total of
3,375,000 shares of common stock as compensation for services. The
fair value of the shares issued (at dates of issuance) totaled
$69,750.
During the second quarter of 2020, the Company sold a total of
8,550,000 shares of common stock (and warrants) in private
placements for total proceeds of $85,490.
During the second quarter of 2020, the Company issued a total of
150,000 shares of common stock as compensation for services. The
fair value of the shares issued (at dates of issuance) totaled
$1,500.
During the third quarter of 2020, the Company sold a total of
7,950,000 shares of common stock (and warrants) in private
placements for total proceeds of $75,500.
During the third quarter of 2020, the Company issued a total of
2,800,000 shares of common stock as compensation for services. The
fair value of the shares issued (at dates of issuance) totaled
$120,000
During the fourth quarter of 2020, the Company sold a total of
5,100,000 shares of common stock (and warrants) in private
placements for total proceeds of $50,990.
In 2019, the Company sold a total of 8,836,667 shares of common
stock (and warrants) in private placements for total proceeds of
$234,490.
In 2019, the Company issued 6,154,333 shares of common stock as
compensation for services. The fair value of the shares issued was
$150,047.
There are no restrictions on the ability of the Subsidiaries to
transfer funds to Genoil in the form of cash dividends, loans or
advances. However, the Subsidiaries are not yet generating income
and the Corporation does not consider them as a source of
revenue.
C. Research and development, patents and licenses,
etc.
Genoil does not presently plan to conduct any major new research
and development, but will continue to refine and fine-tune its
present complement of technologies.
D. Trend information.
Currently Genoil has no sales inventory or production.
E. Critical Accounting Estimates.
The preparation of consolidated financial statements in conformity
with accounting principles generally accepted in the United States
of America (GAAP) requires management to make judgments, estimates
and assumptions that affect the application of accounting policies
and the reported amounts of assets, liabilities, income and
expenses. By their nature, judgments, estimates and assumptions are
subject to measurement uncertainty and changes in such judgments,
estimates and assumptions in future periods could result in a
material change in future financial statements. Actual results may
differ from these estimates.
Judgment is used in situations where there is a choice or
assessment required by management. Estimates and underlying
assumptions are required on an ongoing basis and revisions are
recognized in the year in which such estimates are revised.
G. Safe Harbour.
Not applicable.
Item 6. Directors, Senior Management
and Employees
A. Directors and senior management.
At year end, the following were directors and officers of Genoil,
their residence, their principal occupations within the past five
years, and the periods during which each has served in such
capacity.
Name and Office Held
|
Principal Occupation For Past
Five Years
|
Date of Birth
|
Appointment
|
Number of
Securities
Controlled by
Director and
Percentage of Total
(*)
|
David K. Lifschultz
Chairman and CEO
New York, NY
|
Chief Executive Officer of Genoil Inc. from 2002 to present
|
23-Nov-45
|
25-Feb-02
|
61,254,101
9.56%
|
|
Chairman of the board of directors of Genoil Inc. from 2002 to
present.
|
|
|
|
Bruce S. Abbott
Director and COO
New York, NY
|
President, COO and Director
|
27-Sep-76
|
10-Oct-13
|
6,540,000
1.02%
|
Bengt Koch Director
Morbylanga, Sweden
|
Partner of Merchant Venture Investments
|
29-Oct-37
|
10-Oct-03
|
9,434,620
1.47%
|
Thomas F. Bugg
Calgary, Alberta
|
Business Consultant
|
30-Sep-50
|
02-Sep-20
|
2,000,000
0.31%
|
Jose Garcia Torres Director
|
International Banking
|
18-Aug-49
|
20-Apr-20
|
4,000,000
0.62%
|
Mexico City, Mexico
|
|
|
|
|
Rolando Ramon
Director
|
Business Consultant
|
16-Jan-17
|
28-Jan-19
|
1,750,000
0.27%
|
Lucas, TX
|
|
|
|
|
(*) The “Numbers of Securities Controlled” are comprised by
common shares as of the most recent date, and options, warrants and
convertible notes exercisable/convertible within 60 days from
December 31, 2020.
B. Compensation.
Share-Based Awards
An important part of the Corporation’s current compensation program
is the granting of share-based awards to the Named Executive
Officers (NEOs). These share-based awards have been granted in
replacement, or in lieu, of options to purchase Common Shares
pursuant to the Corporation’s Option Plan. The granting of such
awards is approved by the Board upon recommendation from the
Compensation Committee. The Board considers previous grants when
considering new grants.
Further, in lieu of cash compensation the Company has entered into
agreements (“Price Appreciation Certificates”) with David
Lifschultz and Bruce Abbott whereby, at the request of the
executives, the Company agrees to pay the equivalent sum of the
rise in the Company’s stock price based on the agreed upon number
of shares, from a fixed per share amount to the average of the last
10 trading days (volume weighted average price).
The number of shares reflect a potential salary for the two
executives that only exist if the price of the shares rise above
the price appreciation base amount. The Company has no obligation
to pay the two executives if the stock does not rise. The Company,
at its exclusive option and benefit, can proceed with a private
placement at the share price on the date of exercise and the
executive will subscribe to this private placement for the entire
sum advanced by the Company.
Due to financial constraints, neither of the NEOs has ever received
any cash compensation. Historically, the Corporation granted the
NEOs option-based awards which were to be renewed upon expiration.
The share-based awards granted to Messrs. Lifschultz and Abbott
were granted: (i) as current compensation in lieu of options; or
(ii) in certain instances, in replacement of expired options
granted as compensation for previous years. The outstanding
share-based awards represent 19 years of compensation to Messrs.
Lifschultz and Abbott, the latter of whom was Mr. Lifschultz’s aide
before becoming an officer and director of the Corporation.
Accordingly, their endeavors for the Corporation are to be rewarded
only if the Corporation is successful and that success is reflected
in the trading value of the Common Shares, thereby aligning
management and Shareholder objectives.
Summary Compensation Table
The following table and notes thereto set out information
concerning the compensation paid to the NEOs for the five most
recently completed financial years ended December 31, 2021.
.
|
|
|
|
|
|
|
|
|
|
|
|
|
Non-equity incentive plan compensation ($)
|
|
|
|
|
|
|
|
|
|
|
Name and
Principal Position
|
|
Year
|
|
Salary
($)
|
|
|
Share-based awards
($)(1)
|
|
|
Option-based awards
($)
|
|
|
Annual incentive plans
|
|
|
Long-term incentive plans
|
|
|
Pension value ($)
|
|
|
All Other Compensation ($)
|
|
|
Total Compensation
($)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
David Lifschultz,
|
|
2021
|
|
|
- |
|
|
|
299,892 |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
299,892 |
|
Chairman, Chief Executive Officer and Chief Financial Officer
|
|
2020
2019
2018
2017
|
|
|
-
-
-
-
|
|
|
|
1,556,415
-
3,961,045
2,836,365
|
|
|
|
-
-
-
-
|
|
|
|
-
-
-
-
|
|
|
|
-
-
-
|
|
|
|
-
-
-
-
|
|
|
|
-
-
-
-
|
|
|
|
1,556,415
-
3,961,045
2,836,365
|
|
Bruce Abbott, President and Chief Operating Officer
|
|
2021
2020
2019
2018
|
|
|
-
-
-
-
|
|
|
|
299,892
1,197,243
2,430,766
2,260,870
|
|
|
|
-
-
-
-
|
|
|
|
-
-
-
-
|
|
|
|
-
-
-
-
|
|
|
|
-
-
-
-
|
|
|
|
-
-
-
-
|
|
|
|
299,892
1,197,243
2,430,766
2,260,870
|
|
|
|
2017
|
|
|
- |
|
|
|
1,209,870 |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
1,209,870 |
|
Notes:
(1)
|
The Company accounts for Price Appreciation Certificates as an
equity instrument due to its exclusive option to require a
subscription to the private placement as determined by the fair
value of the instruments using a Black-Scholes pricing model.
|
|
|
|
The fair value of Price Appreciation Certificates granted during
2021, 2020, 2019, 2018 and 2017 was estimated on the dates of grant
using the Black-Scholes pricing model.
|
C. Board practices.
Directors are elected annually to the Board of Directors (the
“Board”) at the Corporation’s Annual General Meeting. Directors may
also, between Annual General Meetings, appoint one or more
additional Directors, provided such number of additional directors
does not exceed 1/3 of the existing number, to serve until the next
Annual General Meeting. No Director has a service contract with
Genoil providing for benefits upon termination of employment.
Duties and Obligations of the Board of Directors
The general duty of Genoil’s Board of Directors is to oversee the
management of Genoil’s business and affairs. In particular, the
Board of Directors is responsible for the following matters:
(a) adopting a strategic planning process which establishes the
Corporation’s long-term goals and strategies, and monitoring the
success of its management in achieving those goals and implementing
the strategy;
(b) identifying the principal risks with respect to all aspects of
the Corporation’s business, ensuring that there are systems in
place to effectively monitor and manage such risks with a view to
its long-term viability, and achieving a proper balance between the
risks incurred and the potential return to its members;
(c) engaging in succession planning, including appointing, training
and monitoring senior management (which includes ensuring that
objectives are in place against which management’s performance can
be measured), establishing and maintaining programs to train and
develop management, providing for the orderly succession of
management, and assessing the performance and contribution of
Genoil’s Chief Executive Officer against mutually established
objectives;
(d) ensuring that there are effective controls and information
systems in place for the Board of Directors to discharge its
responsibilities, such as an audit system which can inform the
Board of Directors about the integrity of the data and the
compliance of the financial information with appropriate accounting
principles, and the timely reporting of developments material to
the Corporation.
Composition of the Board of Directors
As of December 31, 2021, Genoil’s Board of Directors consisted of
Messrs. David Lifschultz, Rolando Ramon, Bruce Abbott, Bengt Koch,
Thomas F. Bugg, and Jose Garcia Torres. Of the Board, Messrs. Koch,
Ramon, Torres, Taylor and Bugg are “independent”. Mr. David
Lifschultz is not independent as he is the Chairman and Chief
Executive Officer of the Corporation. Bruce Abbott is not
considered to be independent as he is the President.
The definition of “independence” that Genoil uses when determining
a director’s independence is derived from National Instrument
58-101, published by the Canadian Securities Administrators and
adopted in all Canadian jurisdictions.
The Board facilitates its exercise of independent supervision over
management by attempting to meet independently from management when
warranted, determining what additional information it needs from
management and seeking outside advice and support as it considers
appropriate. Generally, the Board attempts to ensure that all board
committees are composed in the majority by non-management directors
with consideration being had to the Corporation’s current size and
board composition.
Committees of the Board of Directors
There are currently two committees of the Board of Directors. The
Audit Committee is comprised of two directors, one of whom is a
related party. The Compensation Committee is comprised of all
directors. The mandate and activities of each committee are as
follows:
Audit Committee -
The Audit Committee consists of Bengt Koch and David Lifschultz.
The responsibilities of the Audit Committee include:
(a) assisting the directors with meeting their responsibilities
with respect to financial reporting;
(b) reviewing and reporting to the Board of Directors on all
audited financial statements the Corporation prepares and enhancing
the credibility and objectivity of all financial reports;
(c) reviewing with management and with the external auditor any
proposed changes in major accounting policies, in the presentation
and impact of significant risks and uncertainties, and in key
estimates and judgments of management that may be material to
financial reporting;
(d) questioning management and the external auditor regarding
significant financial reporting issues discussed during the fiscal
period and the method of resolution;
(e) reviewing any problems experienced by the external auditor in
performing the audit, including any restrictions imposed by
management or significant accounting issues on which there was a
disagreement with management; and
(f) reviewing the post-audit or management letters containing the
recommendations of the external auditor and management’s response,
and following up any identified weaknesses.
Relevant Education and Experience
The members of the Audit Committee have the following relevant
education and experience:
|
David K. Lifschultz -
|
Mr. Lifschultz is the former CEO of Lifschultz Industries which was
publicly traded on the NASDAQ Exchange. He had extensive experience
on the Lifschultz Industries audit committee. He is presently CEO
of the Corporation.
|
|
|
|
|
|
Mr. Lifschultz has experience in finance and supervising the
Treasury Department of three public companies: the Corporation,
Lifschultz Industries, and Trans-Air Freight System.
|
|
|
|
|
|
Mr. Lifschultz’s educational experience includes working in the
Treasury Department of Arrow-Lifschultz Freight Forwarders working
in and supervising the accounting, bookkeeping and all other
Treasury functions.
|
|
|
|
|
Bengt Koch
|
Mr. Koch is the former Executive Chairman of Atlantic Container
Lines, a leading Swedish container ship line. Part of
his responsibilities included overseeing the finance, accounting
and treasury functions of the Company.
|
Audit Committee Oversight
Since the commencement of the Corporation’s most recently completed
financial year, there have been no recommendations of the Audit
Committee to nominate or compensate an external auditor, which were
not adopted by the Board.
Compensation
Committee - The Compensation Committee consists of the
entire Board.
The Compensation Committee assists the Board in carrying out its
oversight responsibility with respect to corporate governance and
compensation matters, including making recommendations to the
Corporation’s Board in respect of compensation issues relating to
directors, management and employees of the Corporation. The Board
has approved and adopted a formal charter for the Compensation
Committee. The Compensation Committee’s primary duties and
responsibilities include, but are not limited to, the
following:
|
-
|
reviewing the organization’s structure;
|
|
|
|
|
-
|
management’s succession plans for executive management;
|
|
|
|
|
-
|
developing compensation philosophies and principles; and
|
|
|
|
|
-
|
reviewing and reporting to the Board its recommendations and
determinations of appropriate compensation for the Corporation’s
executive officers.
|
Decisions Requiring the Prior Approval of the Board of
Directors
Each committee of the Board of Directors makes recommendations to
the Board on an ongoing basis. Generally, recommendations from a
committee of the Board of Directors require the approval of the
full Board before they are implemented.
D. Employees.
The Company has been building its internal capabilities.
Genoil utilizes independent contractors to provide engineering and
other services for projects as needed. The operational sites are at
– Two Hills, Alberta and New York, NY.
The Company seeks to work through commission agents who will
receive compensation when revenues are generated.
Genoil has no labour unions and no temporary staff.
E. Share ownership.
There were 640,633,029 Common Shares issued and outstanding as of
December 31, 2021 (2020 – 596,178,029). Information as to share and
option information for directors, officers and key employees is
discussed above in “Item 6. (A) Directors and Senior Management”
and in “Item 6. (B) Compensation.”
Genoil has established a stock option plan with the objective of
advancing its interests by encouraging and enabling the acquisition
of a share interests by its directors, officers, employees and
consultants, in accordance with the policies and rules of the
applicable regulatory authorities. The full text of Genoil’s stock
option plan is attached as an Exhibit to the Form 20-F for 2006
Item 7. Major Shareholders and Related Party
Transactions
A. Major shareholders.
The following table sets forth information as of May 17, 2022, with
respect to each person known to the Corporation to own more than 5%
of its Common Shares. As used in this table, “beneficial ownership”
means the sole or shared power to vote or direct the voting or to
dispose or direct the disposition of any security. For purposes of
this table, a person is deemed to be the beneficial owner of
securities that can be acquired within 60 days from December 31,
2021, through the exercise of any option or warrant. Shares subject
to options or warrants that are currently exercisable or
exercisable within 60 days are deemed outstanding for computing the
ownership percentage of the person holding such options or
warrants, but are not deemed outstanding for computing the
ownership percentage of any other person. The amounts and
percentages are based upon 640,633,029 Common Shares issued and
outstanding.
Class of Share
|
|
Identity of Person or Group
|
|
Number of Shares
Beneficially Owned
|
|
|
Percentage of Share
Stock Beneficially
Owned
|
|
Common Shares
|
|
David K. Lifschultz
|
|
|
61,254,101 |
|
|
|
9.56 |
% |
David Lifschultz has acquired his shareholdings incrementally
during the past years through companies under his control and
personally by way of a series of purchases on the open market and
private placement subscriptions made for the purpose of providing
financial assistance to the Corporation so as to ensure it
continues to meet its financial obligations. Mr. Lifschultz is a
resident in New York.
As of the date of this form and to the knowledge of our directors
and officers, there is no other person or entity who beneficially
owns, directly or indirectly, over more than 5% of the issued and
outstanding Common Shares.
To the best of its knowledge, Genoil is not directly owned or
controlled by another corporation, by any foreign government or by
any natural or legal person.
To the best of its knowledge, Genoil is not aware of any
arrangements which may result in a change of control of Genoil at a
subsequent date.
B. Related party transactions.
|
|
December 31
2021
|
|
|
December 31
2020
|
|
|
|
|
|
|
|
|
Due from related parties
|
|
$ |
220,336 |
|
|
$ |
152,719 |
|
Accrued interest payable to related parties
|
|
|
(3,911,705 |
) |
|
|
(2,964,160 |
) |
Convertible notes
|
|
|
(4,711,764 |
) |
|
|
(4,711,764 |
) |
Due to related parties
|
|
|
(46,875 |
) |
|
|
(64,719 |
) |
Net
|
|
$ |
(8,450,008 |
) |
|
$ |
(7,587,924 |
) |
Transactions with Affiliates, Directors or Officers
Genoil’s approach for transactions with affiliates is that they
must be on terms no less favourable to the Corporation than could
be obtained from unaffiliated third parties.
In the case of transactions involving a director, any of the
Corporation’s directors who, in any way, whether directly or
indirectly, have an interest in a proposed contract or transaction
with it, must disclose the nature and extent of his interest to the
Corporation’s Board and abstain from voting on the approval of the
proposed contract or transaction. If he or she fails to do so, he
or she must account to the Corporation for any profit made as a
consequence of entering into the contract or transaction, unless
the contract was fair and reasonable to the Corporation at the time
it was entered into, and after full disclosure of the nature and
extent of his or her interest, it is approved by the Corporation’s
shareholders by way of a resolution passed by a majority of not
less than two-thirds of the votes cast at a duly convened
shareholders’ meeting. In addition, any of the Corporation’s
directors and officers who holds any office or possesses any
property whereby, whether directly or indirectly, duties or
interests might be created in conflict with his or her duties or
interests as a director or officer, must disclose that fact and the
nature and extent of the conflict. In the case of a director, the
disclosure must be made at a Board meeting.
In the case of transactions involving an officer, the disclosure
must be made in writing to the Corporation’s Chairman at a Board
meeting.
C. Interests of experts and counsel.
Not required as this is an annual report under the Exchange
Act.
Item
8. Financial Information
A. Consolidated statements and other financial
information.
Please see “Item 3 Financial Statements” and Exhibit 19(a) for a
list of the financial statements filed as part of this annual
report statement.
Genoil has neither declared nor paid dividends on any of its
outstanding Common Shares, and does not intend to do so in the
foreseeable future. It intends to retain any future earnings to
finance the expansion of its business. Any future determination to
pay dividends will be at the discretion of the Board of Directors
and will be dependent upon its earnings, capital requirements and
financial position, as well as any other factors deemed relevant by
the Board of Directors.
B. Significant changes.
At the annual and special meeting of the shareholders of Genoil
held on November 14, 2016, a special resolution was passed
authorizing the continuance of the Corporation from a corporation
existing under the laws of Canada to a corporation existing under
the laws of the Country of Curaçao. On May 29, 2019 the Company
finally received a letter of satisfaction from Corporations Canada
approving Genoil’s move to Curacao. However, no such move has been
implemented to date.
Item 9. The Offer and
Listing
A. Offer and listing details.
The following is a summary of the trading history of the Common
Shares on the OTC Bulletin Board (in US dollars) for:
|
·
|
the annual high and low market
prices for the five most recent full financial years; |
|
|
|
|
·
|
the quarterly high and low market
prices for the two most recent full financial years and any
subsequent period; and |
|
|
|
|
·
|
the monthly high and low market
prices for the most recent six months. |
|
|
Price per share on OTC
Bulletin Board
(US $)
|
|
Year
|
|
High
|
|
|
Low
|
|
|
|
|
|
|
|
|
Fiscal year ended December 31, 2021
|
|
|
0.02 |
|
|
|
0.01 |
|
Fiscal year ended December 31, 2020
|
|
|
0.03 |
|
|
|
0.02 |
|
Fiscal year ended December 31, 2019
|
|
|
0.03 |
|
|
|
0.02 |
|
Fiscal year ended December 31, 2018
|
|
|
0.06 |
|
|
|
0.04 |
|
Fiscal year ended December 31, 2017
|
|
|
0.09 |
|
|
|
0.06 |
|
Quarter
|
|
High
|
|
|
Low
|
|
|
|
|
|
|
|
|
Fiscal year ended December 31, 2021
|
|
|
|
|
|
|
First Quarter
|
|
|
0.02 |
|
|
|
0.01 |
|
Second Quarter
|
|
|
0.01 |
|
|
|
0.01 |
|
Third Quarter
|
|
|
0.00 |
|
|
|
0.00 |
|
Fourth Quarter
|
|
|
0.00 |
|
|
|
0.00 |
|
Fiscal year ended December 31, 2020
|
|
|
|
|
|
|
|
|
First Quarter
|
|
|
0.02 |
|
|
|
0.01 |
|
Second Quarter
|
|
|
0.03 |
|
|
|
0.01 |
|
Third Quarter
|
|
|
0.03 |
|
|
|
0.01 |
|
Fourth Quarter
|
|
|
0.02 |
|
|
|
0.01 |
|
Most Recent Six Months
|
|
High
|
|
|
Low
|
|
November 2020
|
|
|
0.00 |
|
|
|
0.00 |
|
December 2020
|
|
|
0.00 |
|
|
|
0.00 |
|
January 2021
|
|
|
0.00 |
|
|
|
0.00 |
|
February 2021
|
|
|
0.00 |
|
|
|
0.00 |
|
March 2021
|
|
|
0.00 |
|
|
|
0.00 |
|
April 2021
|
|
|
0.00 |
|
|
|
0.00 |
|
B. Plan of distribution.
Not required as this is an annual report under the Exchange
Act.
C. Markets.
The issued and outstanding Common Shares are listed and posted for
trading on the OTC Bulletin Board under the symbol “GNOLF”. The
Corporation’s Common Shares are registered shares.
D. Selling shareholders.
Not required as this is an annual report under the Exchange
Act.
E. Dilution.
Not required as this is an annual report under the Exchange
Act.
F. Expenses of the issue.
Not required as this is an annual report under the Exchange
Act.
Item
10. Additional Information
A. Share capital.
Not required as this is an annual report under the Exchange
Act.
B. Memorandum and articles of association.
Genoil was formed by the amalgamation under the Canada Business
Corporations Act (the “CBCA”) of Genoil Inc. and Continental
Fashions Group Inc. (“CFG”), a public company whose shares traded
on the Alberta Stock Exchange. At the time of the merger CFG had no
assets, no liabilities and did not carry on any business. Genoil
was incorporated in April of 1996 under Certificate of
Incorporation no. 324649-3. In June of 1996, it amended and altered
its Memorandum and Articles of Association. This amendment was made
to facilitate a reorganization of its share capital in accordance
with the amalgamation referenced above. The Articles of
Amalgamation, adopted in September of 1996, replaced the Articles
of Incorporation, as amended.
At the Annual and Special Meeting of Shareholders of the
Corporation, held on May 31, 2006, shareholders of the Corporation
passed a special resolution authorizing the Corporation to amend
its Articles to create an additional class of share to be designed
as “Class A Preferred Shares” and to allow for the appointment of
additional directors of the Corporation between shareholder
meetings.
The Articles of Amalgamation are subject to all the provisions of
the CBCA. The CBCA provides that a company incorporated under that
Act has all the powers and capacities of a natural person. The CBCA
further stipulates that a company must not carry on a business that
its articles prohibit. The Corporation’s articles contain no
prohibitions on the nature of businesses that it may carry out.
Thus, it has the power and capacity of a natural person.
The following brief description of provisions of the CBCA, the
Corporation’s amended and restated articles of incorporation and
by-laws do not purport to be complete and are subject in all
respects to the provisions of the CBCA, the Corporation’s restated
articles of incorporation and by-laws.
Regulation SK Item 702 requires the Corporation to state the
general effect of any statute, charter provisions, by-laws,
contract or other arrangements under which any controlling persons,
director or officer of the registrant is insured or indemnified in
any manner against liability which he may incur in his capacity as
such.
Furthermore, the by-laws of the Corporation provide that except in
respect of an action by or on behalf of the Corporation or other
entity to procure a judgment in its favour, the Corporation will
indemnify a director or officer of the Corporation against all
costs, charges, and expenses, including an amount paid to settle an
action or satisfy a judgment, reasonably incurred by the individual
in respect of any civil, criminal, administrative, investigative or
other proceeding in which the individual is involved because of
that association with the Corporation or other entity.
Directors’ Conflicts of
Interest
Section 120 of the CBCA requires every director who is, in any way,
directly or indirectly, interested in one of Genoil’s proposed
material contracts or transactions, to disclose the nature and
extent of the director’s interest in writing or by requesting to
have it entered in the minutes of the meeting of directors or of
meetings of committees of directors.
The CBCA further provides that a director or officer who is
required to disclose an interest may not vote on any resolution to
approve the contract or transaction unless the contract or
transaction, (i) relates primarily to the director’s or officer’s
remuneration as one of the Corporation’s directors, officers,
employees or agents or that of an affiliate, (ii) is for indemnity
or insurance for the director against liability incurred by the
director or officer acting in his or her capacity as a director or
officer, or (iii) is with an affiliate.
Borrowing Powers
The Corporation’s By-Law No. 3 states that the Board of Directors
may exercise borrowing powers provided for in this by-law. These
powers include borrowing money on credit, issuing bonds,
debentures, notes and other indebtedness, giving guarantees on
behalf of the Corporation and granting mortgages by the
Corporation, among others.
Directors
The number of directors shall be not less than one and not more
than nine. The number of directors may be determined from time to
time by an ordinary resolution of the shareholders passed at a duly
convened general meeting. A director is not required to own any of
the Corporation’s shares to be qualified to serve as a director. A
director is not required to retire under any age-limit
requirement.
Upon the termination of each annual general meeting, all the
directors are deemed to cease serving as directors. The number of
directors to be elected at any such meeting will be the number of
directors then in office unless the directors or shareholders
otherwise determine.
If the shareholders remove any director before the expiration of
his or her period of office and appoint another person in his or
her place, that person so appointed shall hold office only during
the remainder of the time that the director in whose place he or
she is appointed would have held the office if he or she had not
been removed. If the shareholders do not appoint another director
to replace the removed director the vacancy may be filled by the
directors.
The directors of the Corporation, between annual meetings, may
appoint one or more additional directors of the Corporation to
serve until the next annual meeting, provided that the number of
additional directors of the Corporation shall not at any time
exceed one-third of the number of directors who held office at the
expiration of the last annual meeting of the Corporation.
The directors, or any committee of directors, may take any action
required or permitted to be taken by them and may exercise any of
the authorities, powers and discretions for the time being vested
in or exercisable by them by way of a resolution either passed at a
meeting at which a quorum is present or consented to in writing
under the applicable section of the CBCA.
The directors may appoint a president, one or more vice-presidents,
a secretary, a treasurer and other officers as determined by the
Board, including assistants to the Board. The directors may specify
the duties of and delegate powers to manage the business and
affairs of the directors to these officers. The Corporation may
also appoint a chairman of the Board, who must also be a director,
and assign the powers and duties assigned to the managing director
or president, under the by-laws, or other powers and duties.
Rights Attached to Shares
The following is a description of the rights, preferences, and
restrictions attached to each class of the Corporation’s
shares:
(a) Unlimited Common Shares – Each Common Share carries the right
to one vote at any meeting of the Corporation’s shareholders.
Dividends are payable on the Common Shares in the discretion of the
Board of Directors. After a period of six years, dividends that
have been paid but remain unclaimed by shareholders shall be
forfeited to the Corporation. In the event of the liquidation,
dissolution or winding-up of the Corporation or any distribution of
Genoil’s assets for the purpose of winding up its affairs, the
Common Shares shall be entitled to receive Genoil’s remaining
property. The Common Shares are not redeemable at the Corporation’s
option or at the option of the holders. There are no sinking fund
provisions respecting the Common Shares. The holders of the Common
Shares are not liable for any further capital calls on such
shares.
(b) Up to 10,000,000 Class A Preferred Shares – The
Class A Preferred Shares may at any time and from time to time be
issued in one or more series, each series consisting of such number
of shares as may, before their issuance, be determined by
resolution of the directors of the Corporation. Subject to the
provisions of the CBCA, the directors of the Corporation may by
resolution fix before the issue of Class A Preferred Shares the
designation, rights, privileges, restrictions and conditions
attaching to each series of the Class A Preferred Shares.
Alteration of the Rights of
Shareholders
No rights, privileges or restrictions attached to the Common Shares
may be altered except with the approval by resolution passed by the
vote of the holders of not less than two-thirds of the votes cast
in respect of a resolution to alter such rights.
There are no limitations in Genoil’s charter on the rights of
non-resident or foreign owners to hold Common Shares of Genoil.
Shareholders’ Meetings
The CBCA requires the directors to call an annual general meeting
of shareholders not later than fifteen months after the last annual
general meeting and no later than six months after the end of the
Corporation’s preceding financial year. The directors may, whenever
they think fit, convene a special meeting.
Notice of a meeting must specify the time and place of a meeting,
and, in case of special business, the general nature of that
business and the text of any resolution. The accidental omission to
give notice of any meeting to, or the non-receipt of any notice by
any of the shareholders entitled to receive notice does not
invalidate any proceedings at that meeting.
All business that is transacted at meetings of shareholders, with
the exception of consideration of the financial statements and
auditor’s report, election of directors, appointment of Genoil’s
auditor is deemed to be special business.
Genoil’s Articles stipulate that business shall be conducted at any
general meeting if there is quorum present at the opening of the
meeting notwithstanding that there ceases to be a quorum present
throughout the meeting. A quorum is shareholders entitled to vote
or proxy holders representing more than 10% of Genoil’s outstanding
shares entitled to vote at the meeting.
Genoil’s Articles stipulate that the Chairman of the Board, or in
his absence, the Corporation’s Managing Director, or in his absence
the Corporation’s President shall preside as chairman of every
general meeting.
Unless the directors otherwise determine, the instrument appointing
a proxyholder shall be deposited at a place specified for that
purpose in the notice convening the meeting, not less than
forty-eight hours before the time for holding the meeting at which
the proxyholder proposes to vote.
Notice of every general meeting should be sent to:
(a) each director;
(b) the Corporation’s auditor;
(c) every shareholder entered in the securities registrar as the
holder of a share or shares carrying the right to vote at such
meetings on the record date or, if no record date was established
by the directors, on the date of mailing such notice; and
(d) every person upon whom the ownership of a share devolves by
reason of his being a legal personal representative or a trustee in
bankruptcy of a shareholder where the shareholder, but for his
death or bankruptcy, would be entitled to vote.
No other person is entitled to receive notice of general
meetings.
There are no limitations to the rights of non-resident or foreign
shareholders to hold or exercise voting rights associated with
Genoil’s securities.
These provisions do not deviate significantly from U.S. law,
insofar as the following matters are concerned:
According to Rule 405 of the Securities Act, the term
“foreign private issuer” means any foreign issuer other than a
foreign government except an issuer meeting the following
conditions:
(a) More than 50 percent of the outstanding voting securities of
such issuer are directly or indirectly owned of record by residents
of the United States; and
(b) Any of the following:
|
(i)
|
The majority of the executive officers or directors are United
States citizens or residents;
|
|
|
|
|
(ii)
|
More than 50 percent of the assets of the issuer are located
in the United States; or
|
|
|
|
|
(iii)
|
The business of the issuer is administered principally in the
United States.
|
Further, the predominant rule in most U.S. jurisdictions is that an
annual meeting must be held every 13 months.
C. Material contracts.
Genoil has entered into the following material contracts in the
ordinary course of business for the two years preceding this
registration statement:
On June 30, 2021, the Company signed an agreement with the Ras
Madrakah Petroleum Industry Company and Beijing Petrochemical
Engineering Company, a subsidiary of Yanchang Petroleum
International Limited to develop a greenfield Genoil Upgrading
refinery with a capacity of 200,000 barrels per day in the Port of
Duqm in the Sultanate of Oman. Estimated to cost approximately $2.4
billion USD, the project will utilize the Genoil Upgrading
Technology “GHU” Process. Genoil will license its proprietary
technology, process design package, training, and advisory
services, as well as proprietary catalyst and equipment supply.
On October 27, 2021, the Company signed an agreement with the
nephew of King Salman to develop a greenfield Genoil Upgrader with
a capacity of 600,000 barrels per day in the Kingdom of Saudi
Arabia. This complex will be one of the largest refining or
upgrading complexes in the world. Genoil estimates the project to
cost approximately $5 billion USD, the project will exclusively be
utilizing Genoil’s Upgrading Technology “GHU” Process. Genoil will
license its proprietary technology, process design package,
training, and advisory services, as well as proprietary catalyst
and equipment supply.
D. Exchange controls.
There is no law or governmental decree or regulation in Canada that
restricts the export or import of capital or affects the remittance
of dividends, interest or other payments to a non-resident holder
of Common Shares, other than withholding tax requirements. See
“Taxation”.
E. Taxation.
Genoil has provided the following summary of the material Canadian
federal and U.S. federal income tax considerations generally
applicable in respect of the holding or disposing of Common Shares.
This summary does not address all possible tax consequences
relating to an investment in its Common Shares. There may be
provincial, territorial, state and local taxes applicable to a
potential shareholder, depending on the shareholder’s particular
circumstances, which are not addressed in this summary. The tax
consequences to any particular holder, including a U.S. Holder of
common shares (defined below) will vary according to the status of
that holder as an individual, trust, corporation, or member of a
partnership, the jurisdiction in which the holder is subject to
taxation, the place where the holder is resident and generally,
according to the holder’s particular circumstances.
U.S. Holder of Common Shares
References to a “U.S. Holder of common shares” in this section
include individuals, corporations, trusts or estates who are
holders of Common Shares and who:
|
·
|
for purposes of the Income Tax Act (Canada) (the “ITA”)
and the Canada-United States Income Tax Convention (1980),
as amended by the protocol signed on July 29, 1997, (the “Treaty”)
are residents of the U.S. and have never been residents of
Canada;
|
|
·
|
for purposes of the U.S. Internal Revenue Code of 1986 (the “Code”)
are U.S. persons;
|
|
·
|
deal at arm’s length with Genoil for purposes of the ITA;
|
|
·
|
will hold the Common Shares as capital property for purposes of the
ITA;
|
|
·
|
will hold the Common Shares as capital assets for purposes of the
Code;
|
|
·
|
do not and will not hold the Common Shares in carrying on a
business in Canada;
|
|
·
|
will not perform independent personal services from a fixed base
situated in Canada; and
|
|
·
|
are not or will not be subject to special provisions of Canadian or
U.S. federal income tax law, including, without limiting the
generality of the foregoing, financial institutions, real estate
investment trusts, shareholders that have a functional currency
other than the U.S. dollar, shareholders that own shares through a
partnership or other pass-through entity, shareholders that hold
shares as part of a straddle, hedge or conversion transaction,
tax-exempt organizations, qualified retirement plans, insurance
companies, shareholders who acquired their shares through the
exercise of employee stock options or otherwise as compensation and
mutual fund companies.
|
The following summary of Canadian federal and U.S. federal income
tax considerations generally applicable to a U.S. Holder of
Genoil’s Common Shares is based on the following, as at the time of
this statement:
|
·
|
the ITA and the Income Tax Regulations (Canada) (the
“Regulations”);
|
|
·
|
published proposals to amend the ITA and the Regulations;
|
|
·
|
published administrative positions and practices of the Canada
Customs and Revenue Agency;
|
|
·
|
published Internal Revenue Service (“IRS”) rulings;
|
|
·
|
published administrative positions of the IRS;
|
|
·
|
published jurisprudence that is considered applicable; and
|
All of the foregoing is subject to material or adverse change, on a
prospective or retroactive basis, at any time. The tax laws of the
various provinces or territories of Canada and the tax laws of the
various state and local jurisdictions of the U.S. are not
considered in this summary.
This summary is not exhaustive of all possible income tax
consequences. The following discussion is for general information
only and is not intended to be, nor should it be construed to be,
legal or tax advice to any holder or prospective holder of Genoil’s
Common Shares and no opinion or representation with respect to any
such holder or prospective holder with respect to the income tax
consequences to any such holder or prospective holder is made.
Accordingly, it is recommended that holders and prospective holders
of the Corporation’s Common Shares consult their own tax advisors
about the Canadian federal and provincial and U.S. federal, state,
local, and foreign tax consequences of purchasing, owning and
disposing of the Corporation’s Common Shares.
Canadian Federal Income Tax
Consequences
Disposition of Common
Shares
Provided that the Common Shares are listed on a “prescribed stock
exchange”, which currently includes the TSX Venture Exchange but
does not include the OTC Markets, a U.S. Holder of Common Shares
will not be subject to tax in Canada under the ITA on capital gains
realized on the disposition of such Common Shares unless the shares
are “taxable Canadian property.” Such Common Shares will be taxable
Canadian property if, in general, at any time during the sixty
month period immediately preceding the disposition, 25% or more of
Genoil’s issued shares of any class (or an option to acquire 25% or
more of the issued shares of any class) were owned by such holder,
or by such holder and persons with whom such holder did not deal at
arm’s length. If the Corporation’s shares are taxable Canadian
property to a U.S. Holder of Common Shares, 50% of any resulting
capital gain realized on the disposition of such shares may be
subject to tax in Canada. However, the Treaty provides that gains
realized by a U.S. Holder of Common Shares on the disposition of
shares of a Canadian corporation will be exempt from federal tax in
Canada unless the value of the Canadian corporation is derived
principally from real property situated in Canada. It is the
current position of the Canada Revenue Agency that a U.S. limited
liability company is not entitled to the benefits of the
Treaty.
Dividend Distributions on
Genoil’s Shares
Dividends paid on Genoil’s Common Shares held by a U.S. Holder of
Common Shares will be subject to Canadian non-resident withholding
tax. The Corporation is required to withhold taxes at source. Under
the Treaty, a withholding rate of 5% is applicable to corporations
resident in the United States and who are beneficial owners of at
least 10% of the voting shares of the Corporation. Under the
Treaty, a withholding rate of 15% is applicable in all other
cases.
United States Federal Income Tax
Consequences
The U.S. federal income tax consequences related to the disposition
and ownership of Common Shares, subject to the Foreign Personal
Holding Company Rules, Passive Foreign Investment Company and
Controlled Foreign Corporation Rules contained in the Code, are
generally as follows:
Disposition of Common
Shares
On a disposition of Common Shares, a U.S. Holder of Common Shares
generally will recognize a gain or loss. The gain or loss will be
equal to the difference between the amount realized on the sale and
the U.S. Holder of Common Share’s adjusted tax basis in those
shares. Any such gain or loss will be a long-term capital gain or
loss if the shareholder has held the shares for more than one year.
Otherwise the gain or loss will be a short-term capital gain or
loss. However, a gain realized on the disposition of Common Shares
may be treated as ordinary income if the company was a “collapsible
corporation” within the meaning of the Code. The gain or loss will
generally be a U.S. source gain or loss.
A collapsible corporation is usually formed to give a short-term
venture the appearance of a long-term investment in order to
portray income as capital gain rather than profit. Such a
corporation is typically formed for the sole purpose of purchasing
property and usually dissolved before the property has generated
substantial income. The Internal Revenue Service treats the income
earned through a collapsible corporation as ordinary income rather
than as capital gain.
Dividend Distributions on
Shares
Dividend distributions (including constructive dividends) paid by
Genoil will be required to be included in the income of a U.S.
Holder of Common Shares to the extent of the Corporation’s current
or accumulated earnings and profits (“E&P”) attributable to the
distribution without reduction for any Canadian withholding tax
withheld from such distributions. Even if such payment is in fact
not converted to U.S. dollars, the amount of any cash distribution
paid in Canadian dollars will be equal to the U.S. dollar value of
the Canadian dollars on the date of distribution based on the
exchange rate on such date. To the extent distributions the
Corporation pays on the Common Shares exceed the Corporation’s
current or accumulated E&P, they will be treated first as a
return of capital up to a shareholder’s adjusted tax basis in the
shares and then as capital gain from the sale or exchange of the
shares.
Dividends paid on the Common Shares generally will not be eligible
for the “dividends received” deduction provided to corporations
receiving dividends from certain U.S. corporations. These dividends
generally may be subject to backup withholding tax, unless a U.S.
Holder of Common Shares furnishes the Corporation with a duly
completed and signed Form W-9. The U.S. Holder of Common Shares
will be allowed a refund or a credit equal to any amount withheld
under the U.S. backup withholding tax rules against the U.S. Holder
of Common Share’s U.S. federal income tax liability, provided the
shareholder furnishes the required information to the IRS.
Foreign Tax
Credit
A U.S. Holder of Common Shares will generally be entitled to a
foreign tax credit or deduction in an amount equal to the Canadian
tax withheld. Dividends paid by Genoil generally will constitute
foreign source dividend income and “passive income” for purposes of
the foreign tax credit, which could reduce the amount of foreign
tax credits available to shareholders. There are significant and
complex limitations that apply to the credit.
Foreign Personal Holding
Company Rules
Special U.S. tax rules apply to a shareholder of a foreign personal
holding company (“FPHC”). Genoil would be classified as a FPHC in
any taxable year if both of the following tests are satisfied:
|
·
|
at least 60% of Genoil’s gross income consists of “foreign personal
holding company income”, which generally includes passive income
such as dividends, interest, royalties, gains from shares and
commodity transactions and rents; and
|
|
·
|
more than 50% of the total voting power of all classes of voting
shares or the total value of outstanding shares is owned directly
or indirectly by five or fewer individuals who are U.S. citizens or
residents.
|
Passive Foreign Investment
Company Rules
Special U.S. tax rules apply to a shareholder of a Passive Foreign
Investment Company (“PFIC”). Genoil could be classified as a PFIC
if, after the application of certain “look through” rules, for any
taxable year, either:
|
·
|
75% or more of the Corporation’s gross income for the taxable year
is “passive income,” which includes interest, dividends and certain
rents and royalties; or
|
|
·
|
the average quarterly percentage, by fair market value of the
Corporation’s assets that produce or are held for the production of
“passive income” is 50% or more of the fair market value of all of
its assets.
|
To the extent Genoil owns at least 25% by value of the shares of
another corporation, it is treated for purposes of the PFIC tests
as owning its proportionate share of the assets of such
corporation, and as receiving directly its proportionate share of
the income of such corporation.
Distributions which constitute “excess distributions” from a PFIC
and dispositions of Common Shares of a PFIC are subject to the
following special rules:
|
·
|
the excess distributions (generally any distributions received by a
U.S. Holder of Common Shares on the shares in any taxable year that
are greater than 125% of the average annual distributions received
by such U.S. Holder of Common Shares in the three preceding taxable
years, or the U.S. Holder of Common Share’s holding period for the
shares, if shorter) or gain would be allocated on a pro rata basis
over a U.S. Holder of Common Share’s holding period for the
shares;
|
|
·
|
the amount allocated to the current taxable year and any taxable
year prior to the first taxable year in which the Corporation is a
PFIC would be treated as ordinary income in the current taxable
year; and
|
|
·
|
the amount allocated to each of the other taxable years would be
subject to the highest rate of tax on ordinary income in effect for
that year and to an interest charge based on the value of the tax
deferred during the period during which the shares are owned.
|
U.S. Holders of Common Shares who actually or constructively own
shares in a PFIC may be eligible to make certain elections which
require them to include income for the PFIC on an annual basis.
Controlled Foreign
Corporation Rules
Generally, if more than 50% of the voting power or total value of
all classes of Genoil’s shares are owned, directly or indirectly,
by U.S. shareholders, who individually own 10% or more of the total
combined voting power of all classes of the Corporation’s shares,
the Corporation could be treated as a controlled foreign
corporation (“CFC”) under Subpart F of the Code. This
classification would require such 10% or greater shareholders to
include in income their pro rata shares of its “Subpart F Income,”
as defined in the Code. In addition, a gain from the sale or
exchange of shares by a U.S. Holder of Common Shares who is or was
a 10% or greater shareholder at any time during the five year
period ending with the sale or exchange will be deemed ordinary
dividend income to the extent that the Corporation’s E&P is
attributable to the shares sold or exchanged.
F. Dividends and paying agents.
Not required as this is an annual report under the Securities
Act.
G. Statement by experts.
Not required as this is an annual report under the Securities
Act.
H. Documents on display.
No longer required
I. Subsidiary information.
Genoil has the following subsidiaries:
|
·
|
Genoil USA Inc., incorporated in
Delaware, United States, which is a wholly owned subsidiary of
Genoil. |
|
·
|
Genoil Emirates LLC, incorporated
in the United Arab Emirates, which will focus upon the fields of
oil and water processing and treatment in the United Arab Emirates.
Emirates LLC is jointly owned by S.B.K. Commercial Business Group
LLC and Genoil. As of December 31, 2021, Emirates LLC had not yet
commenced operations and holds no assets. |
|
·
|
Two Hills Environmental Inc.,
incorporated in Canada and registered in Alberta, which is a wholly
owned subsidiary of Genoil. Two Hills was formed to enter into the
oilfield waste disposal industry by capitalizing upon its current
undeveloped asset base. The asset base comprises a site under which
three salt caverns have been formed in the Lotsberg Formation
beneath the earth’s surface. Such caverns are used in the oilfield
disposal industry as a destination for oilfield wastes. |
Item 11. Quantitative and
Qualitative Disclosures About Market Risk
Genoil is not exposed to cash flow and translation risk due to
changes in the Canadian/United States dollar exchange rate and
interest rate fluctuations at this time due to the fact it does not
currently conduct any material business in Canada or the United
States.
Item 12. Description of
Securities Other than Equity Securities
Not required as this is an annual report under the Securities
Act.
PART II
Item 13.
Defaults, Dividends Arrearages and
Delinquencies
There have been no material defaults in the payment of interest or
principal or any dividend or arrearages or material
delinquencies.
Item
14. Material Modifications to the Rights of Security Holders and
Use of Proceeds
There has been no material modification to the rights of Genoil’s
security holders.
Item
15. Controls and Procedures
(a) Evaluation of
disclosure controls and procedures.
Disclosure controls and procedures are designed to provide
reasonable assurance that all relevant information is gathered and
reported to senior management, including the Chief Executive
Officer (CEO) and Chief Financial Officer (CFO), on a timely basis
so that appropriate decisions can be made regarding public
disclosure.
For the year ended December 31, 2021 the CEO and CFO have evaluated
the effectiveness of the Company’s disclosure controls and
procedures as defined in National Instrument 52-109 of the Canadian
Securities Administrators and as defined in the Securities Exchange
Act of 1934 Rules 13a-15(e) and 15d-15(e)). The Company did not
maintain effective segregation of duties over certain transactions
leading to ineffective supervision and monitoring; and potential
misappropriation of assets. This material weakness affects all
significant accounts.
(b) Management’s annual
report on internal control over financial reporting.
Management is responsible for establishing and maintaining adequate
internal controls over financial reporting of the Company. Internal
controls over financial reporting is a process designed to provide
reasonable assurance regarding the reliability of financial
reporting and the preparation of consolidated financial statements
for external purposes in accordance with accounting principles
generally accepted in the United States of America (“GAAP”).
The Company’s internal controls over financial reporting includes
those policies and procedures that
|
I.
|
pertain to the maintenance of records that, in reasonable detail,
accurately and fairly reflect the transactions and dispositions of
the assets of the company;
|
|
|
|
|
II.
|
provide reasonable assurance that transactions are recorded as
necessary to permit preparation of financial statements in
accordance with US GAAP, and that receipts and expenditures of the
Company are being made only in accordance with authorizations of
management and directors of the Company; and
|
|
|
|
|
III.
|
provide reasonable assurance regarding prevention or timely
detection of unauthorized acquisition, use or disposition of the
Company’s assets that could have a material effect on the financial
statements.
|
A material weakness in internal controls is a significant
deficiency, or combination of significant deficiencies, such that
there is a reasonable possibility that material misstatements of
the financial statements will not be prevented or detected on a
timely basis by the Company.
We note, however, that a control system, no matter how well
conceived and operated, can provide only reasonable, not
absolute, assurance that the objectives of the control system are
met. Because of the inherent limitations in all control systems, no
evaluation of controls can provide absolute assurance that all
control issues including instances of fraud, if any, have been
detected. These inherent limitations include the realities that
judgments in decision-making can be faulty, and breakdowns can
occur because of simple error or mistake. Additionally, controls
can be circumvented by the individual acts of some persons, by
collusion of two or more people, or by management override of the
controls. The design of any system of controls also is based in
part upon certain assumptions about the likelihood of future
events, and there can be no assurance that any design will succeed
in achieving its stated goals under all potential future
conditions. Over time, our control systems may become inadequate
because of changes in conditions, or the degree of compliance with
the policies or procedures may deteriorate. Because of the inherent
limitations in a cost-effective control system, misstatements due
to error or fraud may occur and not be detected and could be
material and require a restatement of our financial statements.
Management conducted an evaluation of the effectiveness of internal
controls over financial reporting based on the framework in
Internal Control-Integrated Framework issued by the Committee of
Sponsoring Organizations of the Treadway Commission (COSO).
Based on this evaluation, management concluded that the Company’s
internal controls over financial reporting were not effective as of
December 31, 2021 due to the following material weakness:
|
·
|
The Company’s staff does not have
sufficient technical accounting knowledge relating to accounting
for income taxes, complex financial instruments and US GAAP and
relied on the assistance of its auditors and financial consultants
in understanding the related accounting and disclosure requirements
on these matters. |
(c) Changes in internal
controls over financial reporting.
There has been no change in the Company’s internal control over
financial reporting that occurred during the Company’s most recent
fiscal period that has materially affected, or is reasonably likely
to materially affect, the Company’s internal control over financial
reporting.
Item 16.
[Reserved]
Not applicable.
A. Audit
Committee Financial Expert
The Board of Directors has determined that Bengt Koch qualifies as
a financial expert. He is an independent director for this
purpose.
B. Code of
Ethics
Genoil has adopted a Code of Conduct that meets the requirements of
the definition of a “Code of Ethics” as that term is defined in
Item 16B(b) of Form 20-F. Genoil’s Code of Conduct is applicable to
all of its employees, including its principal executive officer and
principal financial officer. The Corporation does not currently
employ a principal accounting officer. Its Code of Conduct has been
amended end of December 2007 and copy was attached as Exhibit 11.1
to Form 20-F in that year.
C.
Audit Fees
Michael T. Studer CPA P.C. has served as the Corporation’s auditors
from 2020 onward. The following table summarizes the aggregate fees
for professional audit services and other services rendered by that
firm in the past two years.
In US dollars
|
|
2021
|
|
|
2020
|
|
|
|
|
|
|
|
|
Audit Fees
|
|
$ |
30,000 |
|
|
$ |
45,000 |
|
Audit-Related Fees
|
|
|
- |
|
|
|
- |
|
Tax
|
|
|
- |
|
|
|
- |
|
All Other Fees
|
|
|
- |
|
|
|
- |
|
|
|
|
|
|
|
|
|
|
Total
|
|
$ |
30,000 |
|
|
$ |
45,000 |
|
Audit Fees
Audit fees include fees for professional services rendered in
connection with the audit of Genoil’s annual financial statements
and services provided by the independent auditors in connection
with statutory and regulatory filings or engagements. The figure
for 2020 includes amounts relating to 2020 and previous fiscal
years.
Audit Related Fees
Audit-related fees are generally fees billed for services that are
closely related to the performance of the audit or review of the
financial statements.
Tax Fees
Tax fees are fees for professional services rendered related to tax
compliance, tax advice and tax planning.
All Other Fees
The Company’s audit committee is required to pre-approve all audit
and non-audit services rendered by and approve the engagement fees
and other compensation to be paid to the independent accountant and
its affiliates. When deciding whether to approve these items,
Genoil’s audit committee takes into account whether the provision
of any non-audit service is compatible with the independence
standards under the guidelines of the SEC and of the Independent
Standards Board. To assist in this undertaking, the audit committee
requires the independent accountant to submit a report describing
all relationships the independent accountant has with the Company
and relevant third parties to determine the independent
accountant’s independence.
Exemptions from the Listing Standards for Audit
Committees
Not applicable.
Purchases of Equity Securities by the Issuer and Affiliated
Purchasers
Not applicable.
F. Change in registrant’s Certifying
Accountant
Not applicable.
I. Disclosure Regarding Foreign Jurisdictions
that Prevent Inspections
Not Applicable
PART III
Financial
Statements
The Consolidated Financial Statements for years ended December 31,
2021, 2020 and 2019 are attached as Exhibit 15.1.
Financial Statements
The registrant has elected to provide financial statements using
accounting principles generally accepted in the United States of
America (“GAAP”) for the 2021, 2020 and 2019 year ends.
Exhibits
(a)
|
The Consolidated Financial Statements for the years ended December
31, 2021, 2020 and, 2019
|
|
|
(b)
|
Exhibits
|
Exhibit Number
|
|
Description
|
1.1*
|
|
Articles of Incorporation of Genoil Inc. dated April 1,
1996
|
|
|
|
1.2*
|
|
Articles of Amendment of Genoil Inc. dated June 27,
1996
|
|
|
|
1.3***
|
|
Certificate and Articles of Amalgamation of Genoil Inc. dated
September 5, 1996
|
|
|
|
1.4***
|
|
Certificate and Articles of Amendment of Genoil Inc. dated May 31,
2006
|
|
|
|
1.5***
|
|
By-laws of Genoil Inc. as adopted on May 2, 2006
|
|
|
|
2.2**
|
|
Note and Warrant Purchase Agreement and form of Convertible Note
dated December 23, 2004
|
|
|
|
2.3***
|
|
$750,000 Convertible Promissory Note Dated October 24, 2005 with
Lifschultz Enterprises Co., LLC.
|
|
|
|
2.4***
|
|
$750,000 Convertible Promissory Note Dated December 23, 2005 with
Lifschultz Terminal and Leasing Ltd.
|
|
|
|
2.5****
|
|
$968,825.19 Convertible Promissory Notes Dated October 6, 2006 with
Lifschultz Enterprises Co., LLC, Lifschultz Family Partnership LP
and Sidney B. Lifschultz 1992 Family Trust
|
|
|
|
2.6****
|
|
Stock Option Plan of Genoil Inc., as amended October 25, 2001 and
January 13, 2003, March 30, 2004, June 3, 2005, March 1, 2006, May
31, 2006, and May 14, 2007.
|
|
|
|
2.7 */
|
|
$1,227,355.84 Convertible Promissory Notes Dated October 6, 2009
with Lifschultz Enterprises Co., LLC, Sidney B. Lifschultz 1992
Family Trust, David K. Lifschultz and Bruce Abbott
|
|
|
|
2.8 *//
|
|
Convertible Promissory Notes Dated October 6, 2011 with Lifschultz
Enterprises Co, LLC, Sidney B. Lifschultz 1992 Family Trust, David
K Lifschultz and Bruce Abbott
|
|
|
|
4.1*
|
|
Sample Marketing Agreement
|
|
|
|
4.2*****
|
|
Funding Agreement with David K Lifschultz
|
|
|
|
11.1*****
|
|
Amended Code of Conduct as adopted on December 15, 2007
|
|
|
|
12.1
|
|
Certification of Chief Executive Officer
and Chief Financial Officer pursuant to Section 302 of the
Sarbanes-Oxley Act of 2002
|
|
|
|
13.1
|
|
Certification of Chief Executive Officer
and Chief Financial Officer pursuant to Pursuant to 18 U.S.C.
SECTION 1350
|
|
|
|
14.1
|
|
Independent Auditor’s Consent of Michael
T. Studer CPA P.C.
|
|
|
|
15.1
|
|
Audited Consolidated Financial Statements December 31, 2021
|
* These exhibits were filed with Genoil’s 2003 Form 20‑F.
** This exhibit was filed with Genoil’s 2004 Form 20-F.
*** These exhibits were filed with Genoil’s 2005 Form 20‑F.
**** These exhibits were filed with Genoil’s 2006 Form 20-F.
*****These exhibits were filed with Genoil’s 2007 Form 20-F.
*/ This exhibit was filed with Genoil’s 2009 Form 20-F.
*// This exhibit is filed with Genoil’s 2012 Form 20-F/
SIGNATURES
The registrant hereby certifies that it meets all of the
requirements for filing on Form 20-F and that it has duly caused
and authorized the undersigned to sign this annual report on its
behalf.
Dated May 17, 2022.
|
GENOIL INC. |
|
|
|
|
|
|
By: |
/s/ David K.
Lifschultz |
|
|
|
David K. Lifschultz |
|
|
|
Chief Executive Officer |
|
Genoil (PK) (USOTC:GNOLF)
Historical Stock Chart
From May 2023 to Jun 2023
Genoil (PK) (USOTC:GNOLF)
Historical Stock Chart
From Jun 2022 to Jun 2023